LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 1 of 15: Cell count and relative growth within biological replicate 1. - Dataset - HMS LINCS Database

LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 1 of 15: Cell count and relative growth within biological replicate 1. - Dataset (ID:20237)

Download: Excel (XLSX), Comma-separated (CSV)

<<<<

Select the entities to show:

Small molecules	Cells

|<
<<
Previous
Page 26 of 497
Next
>>
>
626 to 650 of 12420 records
per page:

Cell	Small Molecule	Small Mol Concentration	Small Mol Conc Unit	LJP Library Plate	Replicate	Assay Well	Timepoint	Timepoint Unit	Total Cell Count Before Treatment	Total Cell Count After Treatment	Total Control Cell Count	Relative Cell Count	Relative Growth Rate After Treatment
BT-20	XL147	0.12	uM	LJP5	2	G11	72	hr	1657	5767	5505	1.0475	1.0679
BT-20	XL147	0.12	uM	LJP5	3	G11	72	hr	1657	5712	5505	1.0375	1.0536
BT-20	Saracatinib	0.12	uM	LJP6	1	D11	72	hr	1657	5414	5505	0.9834	0.9762
BT-20	Saracatinib	0.12	uM	LJP6	2	D11	72	hr	1657	5002	5505	0.9085	0.8691
BT-20	Saracatinib	0.12	uM	LJP6	3	D11	72	hr	1657	5322	5505	0.9666	0.9523
BT-20	Selumetinib	0.12	uM	LJP6	1	M11	72	hr	1657	5674	5505	1.0306	1.0437
BT-20	Selumetinib	0.12	uM	LJP6	2	M11	72	hr	1657	5851	5505	1.0627	1.0897
BT-20	Selumetinib	0.12	uM	LJP6	3	M11	72	hr	1657	5252	5505	0.9539	0.9341
BT-20	Sirolimus	0.12	uM	LJP6	1	L17	72	hr	1657	3580	5505	0.6502	0.4996
BT-20	Sirolimus	0.12	uM	LJP6	2	L17	72	hr	1657	3744	5505	0.6800	0.5422
BT-20	Sirolimus	0.12	uM	LJP6	3	L17	72	hr	1657	3528	5505	0.6408	0.4860
BT-20	Sorafenib	0.12	uM	LJP6	1	B11	72	hr	1657	5102	5505	0.9267	0.8951
BT-20	Sorafenib	0.12	uM	LJP6	2	B11	72	hr	1657	4527	5505	0.8222	0.7457
BT-20	Sorafenib	0.12	uM	LJP6	3	B11	72	hr	1657	5235	5505	0.9508	0.9297
BT-20	SU11274	0.12	uM	LJP5	1	J11	72	hr	1657	5733	5505	1.0413	1.0591
BT-20	SU11274	0.12	uM	LJP5	2	J11	72	hr	1657	5510	5505	1.0008	1.0011
BT-20	SU11274	0.12	uM	LJP5	3	J11	72	hr	1657	6005	5505	1.0907	1.1298
BT-20	Fedratinib	0.12	uM	LJP5	1	L05	72	hr	1657	5362	5505	0.9739	0.9627
BT-20	Fedratinib	0.12	uM	LJP5	2	L05	72	hr	1657	5542	5505	1.0066	1.0094
BT-20	Fedratinib	0.12	uM	LJP5	3	L05	72	hr	1657	5283	5505	0.9596	0.9421
BT-20	TGX221	0.12	uM	LJP5	1	H23	72	hr	1657	5253	5505	0.9541	0.9343
BT-20	TGX221	0.12	uM	LJP5	2	H23	72	hr	1657	4829	5505	0.8771	0.8242
BT-20	TGX221	0.12	uM	LJP5	3	H23	72	hr	1657	5546	5505	1.0073	1.0105
BT-20	Torin1	0.12	uM	LJP6	1	O17	72	hr	1657	1941	5505	0.3526	0.0736
BT-20	Torin1	0.12	uM	LJP6	2	O17	72	hr	1657	2224	5505	0.4040	0.1472

|<
<<
Previous
Page 26 of 497
Next
>>
>
626 to 650 of 12420 records
per page:

HMS LINCS Project

LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 1 of 15: Cell count and relative growth within biological replicate 1. - Dataset (ID:20237)